伊沙佐米、泊马度胺与地塞米松治疗来那度胺及蛋白酶体抑制剂难治性多发性骨髓瘤的I/II期研究
该I/II期研究评估了口服蛋白酶体抑制剂伊沙佐米联合泊马度胺和地塞米松在来那度胺及蛋白酶体抑制剂难治性多发性骨髓瘤患者中的安全性与初步疗效。剂量递增确定泊马度胺和伊沙佐米各4 mg、地塞米松20/40 mg为最大耐受剂量。29例可评估患者的总体缓解率为51.7%,中位缓解持续时间16.8个月,中位无进展生存期4.4个月,中位总生存期34.3个月。
要点
- 全口服方案伊沙佐米+泊马度胺+地塞米松在来那度胺/蛋白酶体抑制剂难治性骨髓瘤中总体缓解率达51.7%。
- 中位无进展生存期4.4个月,中位总生存期34.3个月,中位缓解持续时间16.8个月。
- 血液学、胃肠道及全身性不良事件常见,与各单药已知安全性特征一致。
核心结论
- 伊沙佐米联合泊马度胺和地塞米松的全口服方案在来那度胺及蛋白酶体抑制剂难治性多发性骨髓瘤中显示出一定疗效,支持进一步评估。
研究设计与样本
- I/II期研究,剂量递增确定最大耐受剂量为泊马度胺4 mg、伊沙佐米4 mg、地塞米松20/40 mg。
- II期部分在6例患者随机分配至伊沙佐米-泊马度胺-地塞米松后因治疗格局快速变化而重新设计并重新开始。
- 共29例可评估的来那度胺/蛋白酶体抑制剂难治性患者接受该方案治疗。
主要发现
- 总体缓解率(部分缓解或更好)为51.7%。
- 中位缓解持续时间为16.8个月(范围56天至4.1年)。
- 中位无进展生存期为4.4个月(95%CI:3.0-18.4)。
- 中位总生存期为34.3个月(95%CI:19.2至未达到)。
- 血液学、胃肠道及全身性不良事件常见,与各单药副作用特征一致。
临床怎么用
- 对于来那度胺及蛋白酶体抑制剂难治的复发/难治性多发性骨髓瘤患者,可考虑全口服伊沙佐米-泊马度胺-地塞米松方案,但需进一步研究验证。
局限性
- II期部分因治疗格局变化而重新设计并重新开始,可能影响研究连续性。
- 样本量较小(29例可评估患者),需更大规模研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM. Dose escalation established a 4 mg dose of POM and IXA and 20/40 mg dose of DEX as the maximum tolerated dose. The phase II portion of the trial was redesigned and started anew after six patients had been randomized to IXA-POM-DEX due to a rapidly changing treatment landscape. Among the 29 evaluable LEN/PI-refractory patients treated with IXA-POM-DEX in phase I/II, the overall response rate (partial response or better) was 51.7% with a median duration of response of 16.8 months (range 56 days to 4.1 years), median progression-free survival of 4.4 months (95% confidence interval [CI]: 3.0-18.4), and median overall survival of 34.3 months (95% CI: 19.2 to not reached). Hematologic, gastrointestinal, and constitutional adverse events were common and consistent with the side-effect profiles of the individual agents. Our results support further evaluation of this all-oral regimen in relapsed/refractory MM.
引用
- Voorhees PM, Suman VJ, Tuchman SA, et al. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Am J Hematol. 2021. PMID: 34559902. doi:10.1002/ajh.26361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。